Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Vaxart stock price, quote, forecast and news

VXRT
US92243A2006
A2JD8X

Price

0.68
Today +/-
+0
Today %
+0 %
P

Vaxart Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Vaxart, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Vaxart from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Vaxart’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Vaxart. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Vaxart’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Vaxart’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Vaxart’s growth potential.

Vaxart Revenue, EBIT and net profit per share

DateVaxart RevenueVaxart EBITVaxart Net Income
2029e287.49 M undefined0 undefined0 undefined
2028e200.48 M undefined28.97 M undefined0 undefined
2027e212.93 M undefined714,000 undefined0 undefined
2026e46.61 M undefined-123.24 M undefined-67.94 M undefined
2025e22.2 M undefined-115.32 M undefined-77.56 M undefined
2024e15.06 M undefined-100.81 M undefined-88.38 M undefined
20237.38 M undefined-83.35 M undefined-82.47 M undefined
2022100,000 undefined-110.3 M undefined-107.8 M undefined
2021900,000 undefined-69.8 M undefined-70.5 M undefined
20204 M undefined-31 M undefined-32.2 M undefined
20199.9 M undefined-10.9 M undefined-18.6 M undefined
20184.2 M undefined-19.8 M undefined-18.3 M undefined
20175.8 M undefined-10 M undefined-12.5 M undefined
20168.9 M undefined-27.4 M undefined-29.4 M undefined
20159.3 M undefined-25 M undefined-25.4 M undefined
201424.6 M undefined-25.8 M undefined-19.1 M undefined
201368.7 M undefined-10.1 M undefined-11 M undefined
201233.6 M undefined-24 M undefined-8.9 M undefined
201114.8 M undefined-9.8 M undefined-4.5 M undefined
201035 M undefined-1.2 M undefined900,000 undefined
200910.5 M undefined-18 M undefined-18.7 M undefined
20080 undefined-25 M undefined-18.7 M undefined
20070 undefined-44.9 M undefined38.4 M undefined
20060 undefined-61.3 M undefined-64 M undefined
20050 undefined-95.2 M undefined-128.4 M undefined
20040 undefined-81.5 M undefined-50.4 M undefined

Vaxart Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
2323344343465973698310216419523922824323322823419617600000103514336824985494007152246212200287
--47.8326.47-6.9828.2623.73-5.4820.2922.8960.7818.9022.56-4.606.58-4.12-2.152.63-16.24-10.20------250.00-60.00135.71106.06-64.71-62.50-11.11-37.50-20.00125.00-55.56---114.2946.67109.09360.87-5.6643.50
8.704.3511.7611.639.308.7010.1712.3314.4914.4620.5920.1222.0524.2721.0526.3430.0429.8235.0438.7853.98-----80.0088.5792.8639.3925.0087.50100.00--------------
21454469101221334358486470688276950000083113131721900000000000000
-1-2011002-1-12-12-4-911-5-153122-2-81-95-61-44-25-18-1-9-24-10-25-25-27-10-19-10-31-69-110-83-100-115-1230280
-4.35-8.70-2.332.33--2.74-1.45-14.46-11.76-2.44-4.624.60-2.19-0.412.151.325.131.02-1.14------180.00-2.86-64.29-72.73-14.71-104.17-277.78-337.50-200.00-475.00-111.11-775.00---1,185.71-666.67-522.73-267.39-14.00-
0-2110001-2-13-16-13-1713-11-21341041-6-50-128-6438-18-180-4-8-11-19-25-29-12-18-18-32-70-107-82-88-77-67000
---150.00------300.00550.0023.08-18.7530.77-176.47-184.6290.91-114.2933.332,500.00-99.04-700.00733.33156.00-50.00-159.38-147.37---100.0037.5072.7331.5816.00-58.6250.00-77.78118.7552.86-23.367.32-12.50-12.99---
0.10.10.10.20.20.20.30.30.40.30.30.40.50.50.50.50.50.60.70.60.60.90.90.90.90.80.80.70.62.62.83.23.53.50.16.321.688.3121.5127.7144.82000000
-----------------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Vaxart Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Vaxart is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Vaxart provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Vaxart's financial health and stability.

Assets

Vaxart's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Vaxart must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Vaxart after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Vaxart's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016null2017201820192020202120222023
10001-2-13-16-13-1713-11-21341042-6-55-118-59-33-22-180-7-8-11-19-25-29-29-9-18-18-32-70-107-82
0001113466791110991015930100003210000332458
0000000000-6200043-51-20000001000000000000
-30-2-1-3-30-5-14-2-11-34129-34-7-921-8-6-4-41135-12-43-119-1-10212-2-6-8
000000113037160-1-982123137219101576-23224200-117172726
000000112236432230000000000000000000000
000000004700-7004-10000000000000000000000
0100-1-3-9-16-19-126-2518239241078-89-43-26-18639-15-13-3-9-14-30-30-10-14-13-23-59-94-70
00-1-1-1-3-8-4-8-24-23-36-18-21-18-13-5-8-22-3000000-100000000-1-5-9-1
00-7-11-1-417-10-11-31-27-18-18-20135-12-71-34-529207-20-3525531-10-191-1-13260-1-49-2043
00-6021-3311-112-8802-1148-6-63-11-129207-20-3525532-10-191-1-132600-43-1045
000000000000000000000000000000000000000
0-1800-1110-21142332-5-1-31-78001080-34-51-10-600000000-1-30000
0000012381538110001300128921-15-19-7-420026000000191371251715
0-180011501528163938-1-411-30-7812841020-49-71-17-480026017000-1151381251715
00000000-73-43-400000-4-8-20000000018000000000
000000000000000000000000000000000000000
-10000506-1-814-15-200129-7964-217-15131-111-46-5401314-375-32-32-69211316-97-11
-0.940.78-2.19-0.36-2.7-6.85-17.3-20.27-27.93-37.06-16.84-62-0.722.22-9.17115.2-0.52-13.7-93.65-44.13-26.85-18.956.2239.78-15.17-14.9-3.4-9.7-14.3-300-10.16-15.26-13.94-24.97-64.99-104.38-72.32
000000000000000000000000000000000000000

Vaxart stock margins

The Vaxart margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vaxart. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vaxart.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Vaxart's sales revenue. A higher gross margin percentage indicates that the Vaxart retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Vaxart's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Vaxart's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Vaxart's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Vaxart. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Vaxart's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Vaxart Margin History

Vaxart Gross marginVaxart Profit marginVaxart EBIT marginVaxart Profit margin
2029e100 %0 %0 %
2028e100 %14.45 %0 %
2027e100 %0.34 %0 %
2026e100 %-264.39 %-145.76 %
2025e100 %-519.42 %-349.35 %
2024e100 %-669.59 %-587.04 %
2023100 %-1,129.52 %-1,117.56 %
2022100 %-110,300 %-107,800 %
2021100 %-7,755.56 %-7,833.33 %
2020100 %-775 %-805 %
2019100 %-110.1 %-187.88 %
2018100 %-471.43 %-435.71 %
2017100 %-172.41 %-215.52 %
2016100 %-307.87 %-330.34 %
2015100 %-268.82 %-273.12 %
201485.37 %-104.88 %-77.64 %
201325.62 %-14.7 %-16.01 %
201241.37 %-71.43 %-26.49 %
201190.54 %-66.22 %-30.41 %
201088.86 %-3.43 %2.57 %
200980.95 %-171.43 %-178.1 %
2008100 %0 %0 %
2007100 %0 %0 %
2006100 %0 %0 %
2005100 %0 %0 %
2004100 %0 %0 %

Vaxart Stock Sales Revenue, EBIT, Earnings per Share

The Vaxart earnings per share therefore indicates how much revenue Vaxart has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vaxart earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vaxart's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vaxart’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vaxart's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Vaxart Revenue, EBIT and net profit per share

DateVaxart Sales per ShareVaxart EBIT per shareVaxart Earnings per Share
2029e1.63 undefined0 undefined0 undefined
2028e1.13 undefined0 undefined0 undefined
2027e1.2 undefined0 undefined0 undefined
2026e0.26 undefined0 undefined-0.38 undefined
2025e0.13 undefined0 undefined-0.44 undefined
2024e0.09 undefined0 undefined-0.5 undefined
20230.05 undefined-0.58 undefined-0.57 undefined
20220 undefined-0.86 undefined-0.84 undefined
20210.01 undefined-0.57 undefined-0.58 undefined
20200.05 undefined-0.35 undefined-0.36 undefined
20190.46 undefined-0.5 undefined-0.86 undefined
20180.67 undefined-3.14 undefined-2.9 undefined
201758 undefined-100 undefined-125 undefined
20162.54 undefined-7.83 undefined-8.4 undefined
20152.66 undefined-7.14 undefined-7.26 undefined
20147.69 undefined-8.06 undefined-5.97 undefined
201324.54 undefined-3.61 undefined-3.93 undefined
201212.92 undefined-9.23 undefined-3.42 undefined
201124.67 undefined-16.33 undefined-7.5 undefined
201050 undefined-1.71 undefined1.29 undefined
200913.13 undefined-22.5 undefined-23.38 undefined
20080 undefined-31.25 undefined-23.38 undefined
20070 undefined-49.89 undefined42.67 undefined
20060 undefined-68.11 undefined-71.11 undefined
20050 undefined-105.78 undefined-142.67 undefined
20040 undefined-90.56 undefined-56 undefined

Vaxart business model

Vaxart Inc is a US biotechnology company that was founded in 2004 and is based in South San Francisco, California. The company specializes in the development of oral vaccines and therapeutics. Vaxart is one of the most popular companies on Eulerpool.com.

Vaxart SWOT Analysis

Strengths

Vaxart Inc is built upon an innovative vaccine platform that uses oral tablets for vaccine administration. This approach offers several advantages, including ease of use, elimination of the need for needles, and increased patient compliance. By utilizing this unique technology, the company has the potential to revolutionize the way vaccines are administered.

Vaxart Inc has a diverse pipeline of vaccine candidates targeting various infectious diseases. This broad development portfolio mitigates the risk associated with focusing on a single product. With ongoing research and development efforts, the company can capitalize on a wide range of market opportunities and potentially address unmet medical needs.

Weaknesses

Vaxart Inc is a relatively young company and may lack the extensive commercialization experience of more established vaccine manufacturers. This could pose challenges in effectively bringing their products to market, establishing partnerships, and navigating regulatory processes. Developing strong marketing and distribution strategies will be crucial for the company's success.

Vaxart Inc relies on external manufacturers for the production of its vaccine candidates. This reliance on third-party facilities introduces a level of dependency and potential supply chain risks. Ensuring consistent and high-quality manufacturing processes will be essential for meeting market demand and maintaining product efficacy and safety.

Opportunities

The global vaccines market is experiencing significant growth due to increasing awareness about preventive healthcare, expanding immunization programs, and rising disease prevalence. Vaxart Inc can leverage this favorable market trend by successfully developing and commercializing its vaccine candidates, potentially capturing a significant market share and achieving financial success.

Establishing strategic partnerships with pharmaceutical companies, government agencies, and research institutions can provide Vaxart Inc with access to additional resources, expertise, and funding. Collaborations can accelerate the company's product development, enhance its market reach, and increase its competitive advantage. Building strong relationships with key stakeholders becomes crucial for long-term success.

Threats

The vaccine market is highly competitive, with numerous established players and emerging biopharmaceutical companies. Vaxart Inc may face intense competition in terms of vaccine efficacy, safety, pricing, and market access. Staying ahead of competitors requires continuous innovation, effective marketing strategies, and a strong focus on addressing customer needs and demands.

Developing and commercializing vaccines involve stringent regulatory requirements and safety evaluations. Vaxart Inc must navigate complex regulatory pathways, ensuring compliance with regulations and demonstrating the efficacy and safety of its products. Any adverse events or safety concerns can significantly impact the reputation and market acceptance of the company's vaccine candidates.

Vaxart historical P/E ratio, EBIT, and P/S ratio.

Vaxart shares outstanding

The number of shares was Vaxart in 2023 — This indicates how many shares 144.82 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vaxart earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vaxart's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vaxart’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vaxart's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Vaxart Stock splits

In Vaxart's history, there have been no stock splits.

Vaxart dividend history and estimates

In 2023, Vaxart paid a dividend amounting to 0 USD. Dividend means that Vaxart distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Vaxart provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Vaxart’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Vaxart's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Vaxart Dividend History

DateVaxart Dividend
201273.13 undefined

Vaxart dividend payout ratio

In 2023, Vaxart had a payout ratio of 0%. The payout ratio indicates the percentage of the company's profits that Vaxart distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Vaxart represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Vaxart could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Vaxart's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Vaxart Payout Ratio History

DateVaxart Payout ratio
2029e0 %
2028e0 %
2027e0 %
2026e0 %
2025e0 %
2024e0 %
20230 %
20220 %
20210 %
20200 %
20190 %
20180 %
20170 %
20160 %
20150 %
20140 %
20130 %
2012-2,138.25 %
20110 %
20100 %
20090 %
20080 %
20070 %
20060 %
20050 %
20040 %
Unfortunately, there are currently no price targets and forecasts available for Vaxart.

Vaxart latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-0.14 -0.14  (1.96 %)2024 Q1
12/31/2023-0.15 -0.12  (18.86 %)2023 Q4
9/30/2023-0.18 -0.11  (38.96 %)2023 Q3
6/30/2023-0.18 -0.16  (12.85 %)2023 Q2
3/31/2023-0.19 -0.19  (0.21 %)2023 Q1
12/31/2022-0.23 -0.18  (22.45 %)2022 Q4
9/30/2022-0.25 -0.23  (7.03 %)2022 Q3
6/30/2022-0.21 -0.23  (-7.38 %)2022 Q2
3/31/2022-0.17 -0.2  (-20.63 %)2022 Q1
12/31/2021-0.17 -0.17  (1.96 %)2021 Q4
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the Vaxart stock

Eulerpool World ESG Rating (EESG©)

45/ 100

🌱 Environment

48

👫 Social

55

🏛️ Governance

33

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Vaxart list of shareholders

%
Name
Stocks
Change
Date
8.70 % RA Capital Management, LP15,384,61515,384,6151/18/2024
3.98 % The Vanguard Group, Inc.7,044,97188,13112/31/2023
1.11 % Geode Capital Management, L.L.C.1,962,033175,39812/31/2023
1.00 % BlackRock Institutional Trust Company, N.A.1,773,471012/31/2023
0.38 % Finney Michael J670,8407,3756/26/2023
0.28 % Citadel Advisors LLC499,018494,02612/31/2023
0.28 % GSA Capital Partners LLP488,496205,55912/31/2023
0.26 % State Street Global Advisors (US)466,545012/31/2023
0.20 % Morgan Stanley & Co. LLC354,052-32,57112/31/2023
0.19 % Northern Trust Investments, Inc.334,13469,41612/31/2023
1
2
3
4
5
...
10

Vaxart Executives and Management Board

Dr. James Cummings57
Vaxart Chief Medical Officer
Compensation 1.93 M
Dr. Sean Tucker55
Vaxart Senior Vice President, Chief Scientific Officer
Compensation 1.89 M
Mr. W. Mark Watson72
Vaxart Independent Director
Compensation 388,629
Dr. Elaine Heron75
Vaxart Independent Director
Compensation 333,335
Mr. Robert Yedid65
Vaxart Independent Director
Compensation 240,174
1
2

Most common questions regarding Vaxart

What values and corporate philosophy does Vaxart represent?

Vaxart Inc represents values of innovation, commitment, and growth. With a corporate philosophy focused on advancing groundbreaking oral vaccines, Vaxart aims to revolutionize the field of infectious diseases prevention. Through their proprietary oral tablet platform, the company strives to provide effective and accessible vaccine solutions globally. Vaxart Inc prides itself on its dedication to scientific excellence, aiming to deliver safe and convenient vaccines to address unmet medical needs. With a diverse and experienced team, Vaxart fosters a culture of collaboration and remains committed to driving positive changes in public health.

In which countries and regions is Vaxart primarily present?

Vaxart Inc is primarily present in the United States.

What significant milestones has the company Vaxart achieved?

Vaxart Inc has achieved significant milestones in its history. The company gained recognition for its innovative approach to vaccine development. One of the notable milestones includes the successful completion of Phase 2 clinical trials for their oral vaccine candidate, which demonstrated promising results. Vaxart Inc also entered into a collaboration agreement with a major pharmaceutical company to develop a potential universal flu vaccine. Additionally, the company received a grant from the Biomedical Advanced Research and Development Authority (BARDA) to support the development of COVID-19 vaccine candidates. These milestones highlight Vaxart Inc's commitment to advancing immunization solutions and position it as a key player in the development of preventive healthcare.

What is the history and background of the company Vaxart?

Vaxart Inc is a biotechnology company based in California, USA. Founded in 2004, they specialize in developing oral vaccines for a wide range of infectious diseases. Vaxart has made significant advancements in the field of immunization through their innovative platform, which enables the delivery of vaccines via tablets rather than injections. Their unique approach has gained recognition and partnerships with various organizations, including the US Department of Defense and National Institutes of Health. With a strong focus on developing effective and accessible vaccines, Vaxart Inc aims to make a positive impact on global healthcare.

Who are the main competitors of Vaxart in the market?

Some of the main competitors of Vaxart Inc in the market are Moderna Inc, Pfizer Inc, Johnson & Johnson, Novavax Inc, and Inovio Pharmaceuticals Inc.

In which industries is Vaxart primarily active?

Vaxart Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Vaxart?

Vaxart Inc is a clinical-stage biotechnology company that specializes in the development of oral vaccines. The company's innovative business model focuses on the creation of oral recombinant vaccines, which are administered by pill rather than injection. Vaxart aims to revolutionize the way vaccines are delivered by providing a convenient and needle-free alternative. By leveraging their proprietary technology platform, the company can rapidly develop and produce vaccines for both infectious diseases and emerging public health threats. Vaxart's business model positions them as a leader in the development of oral vaccines, offering a promising solution to enhance global vaccination efforts.

What is the P/E ratio of Vaxart 2024?

The Vaxart P/E ratio is -1.11.

What is the P/S ratio of Vaxart 2024?

The Vaxart P/S ratio is 6.49.

What is the AlleAktien quality score of Vaxart?

The AlleAktien quality score for Vaxart is 6/10.

What is the revenue of Vaxart 2024?

The expected Vaxart revenue is 15.06 M USD.

How high is the profit of Vaxart 2024?

The expected Vaxart profit is -88.38 M USD.

What is the business model of Vaxart

Vaxart Inc is a biopharmaceutical company that focuses on the development of oral vaccines and therapeutics. The company uses its proprietary technology platform to provide vaccines and therapeutics that have a broader impact and efficacy than conventional injectable vaccines. Vaxart's business model is based on the development of vaccines and therapeutics for human use. The company is working on the development of vaccines against a variety of infectious diseases such as influenza, Covid-19, and other respiratory diseases, as well as against chronic diseases such as cancer and HIV. Vaxart's technology platform enables rapid and cost-effective development of vaccine candidates and therapeutics, thereby enhancing the effectiveness of vaccines and therapeutics. Vaxart collaborates closely with government agencies, academic institutions, and other pharmaceutical manufacturers to advance research and development efforts and license its technology platform and products. The company has also developed a wide range of products based on its technology platform. Products of Vaxart include: - Oral Covid-19 vaccine: Vaxart has developed an oral Covid-19 vaccine that is currently being tested in clinical trials. The vaccine is based on the company's proprietary technology platform and is capable of providing broader immunity against Covid-19 than conventional injected vaccines. - Oral influenza vaccine: Vaxart has also developed an oral vaccine that is effective against influenza and is currently being tested in clinical trials. The vaccine is based on the company's proprietary technology platform and shows high efficacy in preclinical tests. - Oral HIV vaccine: Vaxart has also developed an oral HIV vaccine that demonstrates high efficacy in preclinical tests. The vaccine is based on the company's proprietary technology platform and is currently in clinical trials. - Oral RSV vaccine: Vaxart is working on the development of an oral vaccine against Respiratory Syncytial Virus (RSV). The vaccine is based on the company's proprietary technology platform and shows promising results in preclinical tests. - Oral HPV vaccine: Vaxart is also working on the development of an oral vaccine against Human Papillomavirus (HPV), which causes cervical cancer. The vaccine is based on the company's proprietary technology platform and is currently in preclinical tests. In summary, Vaxart Inc has a promising business model based on the development of oral vaccines and therapeutics. The company has successfully utilized its technology platform to bring a wide range of products to the market that can be used against infectious diseases and chronic conditions. With its promising pipeline, Vaxart has significant potential to fundamentally change and expand the vaccine and therapy market.

What is the Vaxart dividend?

Vaxart pays a dividend of 0 USD distributed over payouts per year.

How often does Vaxart pay dividends?

The dividend cannot currently be calculated for Vaxart or the company does not pay out a dividend.

What is the Vaxart ISIN?

The ISIN of Vaxart is US92243A2006.

What is the Vaxart WKN?

The WKN of Vaxart is A2JD8X.

What is the Vaxart ticker?

The ticker of Vaxart is VXRT.

How much dividend does Vaxart pay?

Over the past 12 months, Vaxart paid a dividend of 73.13 USD . This corresponds to a dividend yield of about 10,833.78 %. For the coming 12 months, Vaxart is expected to pay a dividend of 0 USD.

What is the dividend yield of Vaxart?

The current dividend yield of Vaxart is 10,833.78 %.

When does Vaxart pay dividends?

Vaxart pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vaxart?

Vaxart paid dividends every year for the past 0 years.

What is the dividend of Vaxart?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vaxart located?

Vaxart is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vaxart kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vaxart from 11/8/2012 amounting to 6.648 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2012.

When did Vaxart pay the last dividend?

The last dividend was paid out on 11/8/2012.

What was the dividend of Vaxart in the year 2023?

In the year 2023, Vaxart distributed 0 USD as dividends.

In which currency does Vaxart pay out the dividend?

The dividends of Vaxart are distributed in USD.

All fundamentals about Vaxart

Our stock analysis for Vaxart Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vaxart Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.